CERDELGA Drug Patent Profile

When do Cerdelga patents expire, and what generic alternatives are available?

Cerdelga is a drug marketed by Genzyme Corp and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and sixty-six patent family members in forty-four countries.

The generic ingredient in CERDELGA is eliglustat tartrate. There are eight drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the eliglustat tartrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cerdelga

A generic version of CERDELGA was approved as eliglustat tartrate by AIZANT on September 8^th, 2021.

Summary for CERDELGA

International Patents:	166
US Patents:	5
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	58
Clinical Trials:	6
Patent Applications:	668
Drug Prices:	Drug price information for CERDELGA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for CERDELGA
What excipients (inactive ingredients) are in CERDELGA?	CERDELGA excipients list
DailyMed Link:	CERDELGA at DailyMed

See drug prices for CERDELGA

Recent Clinical Trials for CERDELGA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Taiwan University Hospital	N/A
Sanofi	N/A
Sanofi	Phase 3

See all CERDELGA clinical trials

Pharmacology for CERDELGA

Drug Class	Glucosylceramide Synthase Inhibitor
Mechanism of Action	Cytochrome P450 2D6 Inhibitors Glucosylceramide Synthase Inhibitors P-Glycoprotein Inhibitors

Paragraph IV (Patent) Challenges for CERDELGA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
CERDELGA	Capsules	eliglustat tartrate	84 mg	205494	6	2018-08-20

US Patents and Regulatory Information for CERDELGA

CERDELGA is protected by eight US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Genzyme Corp	CERDELGA	eliglustat tartrate	CAPSULE;ORAL	205494-001	Aug 19, 2014	AB	RX	Yes	Yes
Genzyme Corp	CERDELGA	eliglustat tartrate	CAPSULE;ORAL	205494-001	Aug 19, 2014	AB	RX	Yes	Yes				Y
Genzyme Corp	CERDELGA	eliglustat tartrate	CAPSULE;ORAL	205494-001	Aug 19, 2014	AB	RX	Yes	Yes			Y	Y
Genzyme Corp	CERDELGA	eliglustat tartrate	CAPSULE;ORAL	205494-001	Aug 19, 2014	AB	RX	Yes	Yes
Genzyme Corp	CERDELGA	eliglustat tartrate	CAPSULE;ORAL	205494-001	Aug 19, 2014	AB	RX	Yes	Yes

Expired US Patents for CERDELGA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Genzyme Corp	CERDELGA	eliglustat tartrate	CAPSULE;ORAL	205494-001	Aug 19, 2014
Genzyme Corp	CERDELGA	eliglustat tartrate	CAPSULE;ORAL	205494-001	Aug 19, 2014
Genzyme Corp	CERDELGA	eliglustat tartrate	CAPSULE;ORAL	205494-001	Aug 19, 2014
Genzyme Corp	CERDELGA	eliglustat tartrate	CAPSULE;ORAL	205494-001	Aug 19, 2014

International Patents for CERDELGA

See the table below for patents covering CERDELGA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2018386182
Brazil	112020011056
Canada	3083663
China	111479591
China	116139130

Supplementary Protection Certificates for CERDELGA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1409467	C300738	Netherlands		PRODUCT NAME: ELIGLUSTAT, OF FYSIOLOGISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/14/974 20150119
1409467	CR 2015 00035	Denmark		PRODUCT NAME: ELIGLUSTAT, EVENTUELT I FORM AF ET FYSIOLOGISK ACCEPTABELT SALT, HERUNDER ELIGLUSTAT (SOM TARTRAT); REG. NO/DATE: EU/1/14/974 20150119
1409467	92717	Luxembourg		PRODUCT NAME: ELIGLUSTAT, EVENTUELLEMENT SOUS LA FORME D UN SEL PHYSIOLOGIQUEMENT ACCEPTABLE. FIRST REGISTRATION: 20150121
1409467	C20150027 00161	Estonia		PRODUCT NAME: ELIGLUSTAAT;REG NO/DATE: EU/1/14/974 21.01.2015
1409467	1590029-3	Sweden		PRODUCT NAME: ELIGLUSTAT, VALFRITT I FORM AV ETT FYSIOLOGISKT GODTAGBART SALT; REG. NO/DATE: EU/1/14/974 20150121

CERDELGA (eliglustat) market dynamics and financial trajectory: exclusivity, competitive pressure, pricing, and revenue outlook

Last updated: July 24, 2026

CERDELGA (eliglustat) is a niche, high-exclusivity oral therapy for Gaucher disease type 1 (GD1) used in patients who are CYP2D6 metabolizer-matched. Commercial trajectory is shaped by (1) payer coverage tightness around a specialty, genotype-driven indication, (2) slow-switching in established Gaucher centers, and (3) competition from substrate reduction alternatives and potential future pipeline entrants. Patent and regulatory exclusivity have largely determined entry risk for branded continuation and generic/substitutable disruption, while cost pressures influence net-to-gross and channel mix.

---

What is CERDELGA (eliglustat) used for, and how does the patient selection model drive market size?

CERDELGA is an oral substrate reduction therapy indicated for adult patients with Gaucher disease type 1 who are CYP2D6 metabolizer status-matched.

How CYP2D6 genotype matching constrains addressable patients

The practical market is limited by:

• Requirement for CYP2D6 genotyping or validated phenotype testing.
• Dosing stratification by metabolizer status (ultra-rapid, extensive, intermediate, poor), with drug interaction constraints.
• Exclusion or restricted use in certain patients due to contraindicated concomitant therapies and metabolizer/inhibitor interactions.

Commercial implication: growth depends on physician willingness to build testing workflows and on payer acceptance of genotype-driven prescribing. In Gaucher, prescriber behavior is typically conservative, with patients staying on therapy unless efficacy, tolerability, or reimbursement materially changes.

Where CERDELGA fits clinically versus enzyme replacement

Most GD1 treatment landscapes split into:

• Enzyme replacement therapy (ERT) via IV infusions
• Oral SRT options, including eliglustat

Oral convenience supports uptake where adherence and drug interaction management are feasible, but payer reimbursement and center protocols can still favor ERT for some patients, especially those already stable on IV regimens.

---

What patents protect CERDELGA, and when does eliglustat lose exclusivity?

CERDELGA’s exclusivity and patent landscape is the primary determinant of near-term branded durability versus generic substitution risk. Market dynamics track the “entry-risk calendar” because payer and specialty pharmacy channel behavior typically shifts once credible Paragraph IV or authorization-for-ANDA pathways emerge.

Exclusivity timeline framework

For small molecule branded products, the relevant milestone stack usually includes:

• Composition and/or method-of-use patents covering active ingredient and specific therapeutic embodiments
• Formulation and manufacturing patents (process, polymorphs, stability, or improved dosage forms)
• Regulatory exclusivities (e.g., NDA exclusivity) that can delay FDA approval pathways even after some patent cliffs

Commercial implication: CERDELGA’s sales durability typically correlates with the absence of FDA-accepted generic challenges and with strong Orange Book coverage for blocking patents at time of potential entry.

How to assess exclusivity risk for market forecasting

A reliable “generic threat score” is built from:

• Orange Book breadth: number of listed patents and remaining terms
• Patent types: whether blocking patents are composition vs. weaker dependent claims
• Litigation status: active challenges, settlements, and consent decrees
• Exclusivity triggers: any pediatric, listed exclusivity, or other regulatory exclusivity overlays

---

What is the Orange Book status of CERDELGA (eliglustat), and which patent types matter most for blocking entry?

Orange Book status determines the ability of FDA applicants to qualify patents for challenges and the strength of blocking arguments in litigation.

Patent-type sensitivity for substrate reduction products

For SRT like eliglustat, market impact tends to come from:

• Composition-of-matter claims that directly protect the active ingredient
• Method-of-treatment claims that track patient selection criteria
• Formulation and dosing claims that can delay “at-risk” launch even if composition patents are challenged successfully

Commercial implication: if Orange Book lists multiple active patents with staggered expiration, launch timing becomes uncertain and can deter payer-driven substitution and pharmacy switching.

---

How strong is the CERDELGA patent estate for generic entry and biosimilar-style risk?

CERDELGA is a small molecule, so biosimilar dynamics do not apply. The relevant “biologic-style” analog is not biosimilar risk but rather:

• Whether generic substitution faces a robust blocking patent wall
• Whether interchangeability is legally and clinically acceptable in CYP2D6-stratified dosing frameworks

Why generic entry is harder in CYP-stratified products

Even if an ANDA can be filed, market adoption depends on:

• Label compatibility with metabolizer-based dosing instructions
• Bioequivalence for multiple relevant dosing regimens and interaction constraints
• Pharmacy and physician confidence in switching stable patients

Commercial implication: strong patent coverage plus complex genotype-based label reduces switching speed, even post-legal entry.

---

What patent litigation affects CERDELGA, and how do settlements shape sales curves?

For branded products in niche specialty indications, litigation outcomes drive:

• “No-landing” scenarios where generic entry is delayed through dismissal, settlement, or design-around invalidation arguments
• Timetables where court calendars and consent decrees cause discontinuous shifts in channel expectations

Settlement dynamics that influence market performance

When settlements occur, they often set:

• Timed entry dates for generics
• Restrictions on launch packaging, labeling, or manufacturing until a later date
• Non-infringement carve-outs that can reduce damages exposure for the generic

Commercial implication: a settlement that pushes entry beyond the next payer contracting cycle can lock branded revenues for an additional year or more.

---

What generic entry risks exist for CERDELGA, and what launch scenarios are most realistic?

Generic entry scenarios for eliglustat typically hinge on:

1. Timing: how soon the last blocking patent expires and whether there are enforceable regulatory exclusivities.
2. Approval pathway: whether an ANDA can qualify without a successful court challenge.
3. Label and prescriber acceptance: genotype matching is still part of practice.

Market behavior after legal entry

Even after “first generic approval,” uptake can be slow if:

• Payers prefer formulary rebates rather than cheapest acquisition
• Specialty pharmacies require conversion to avoid reimbursement churn
• Physicians worry about maintaining stable dosing and interaction management

Commercial implication: branded revenues may decay gradually (not cliff-like) when patent barriers fall but payer contracting shifts only over subsequent cycles.

---

How does CERDELGA compare with competing Gaucher therapies on market adoption and payer dynamics?

The competitive set matters for market share, pricing pressure, and net revenue trajectory. For GD1, the key axes are:

• Oral vs IV route convenience
• Patient suitability based on comorbidities and interaction profile
• Total cost of care including infusion resources vs oral monitoring
• Clinical outcomes in real-world settings and center protocols

What drives switching away from CERDELGA

Switching away usually occurs when:

• Drug-drug interaction risk rises with patient aging or polypharmacy
• Patients have suboptimal response or tolerability
• Payers narrow oral options or increase prior authorization barriers

What drives switching to CERDELGA

Uptake increases when:

• Centers standardize CYP2D6 testing workflow
• Payer coverage improves for genotype-matched SRT
• Patients value oral convenience and adherence benefits

---

What is CERDELGA’s financial trajectory: revenue drivers, channel mix, and pricing pressure?

CERDELGA’s financial performance is typically dominated by:

• US specialty channel penetration (high-cost specialty pharmacy distribution)
• Net pricing influenced by rebate arrangements and payer formulary placement
• Patient retention in a chronic genetic disease (low churn but sensitivity to access)

Key revenue levers that shape annual sales

1. New patient starts: gated by diagnosis rates, genotype testing infrastructure, and center preferences.
2. Persistence: chronic therapy reduces churn, but interaction constraints can force discontinuation.
3. Access and reimbursement: prior authorization criteria, step therapy, and restrictions on metabolizer subgroups.
4. Pricing environment: specialty drug pricing scrutiny, affordability initiatives, and contracting pressure.

How market dynamics translate into a sales curve

• In stable exclusivity periods, revenues usually follow modest growth or plateau because the addressable patient pool is capped by genotype constraints.
• During periods of heightened competitive or access pressure, net sales can compress even if gross list pricing holds, due to rebates and tighter payer rules.

---

When do payer and reimbursement changes typically move CERDELGA net sales, and how can that be forecast?

Payer dynamics can change faster than legal exclusivity. Forecasting needs to track:

• Formulary placement (preferred vs non-preferred)
• Prior authorization stringency and permitted patient subgroups
• Specialty pharmacy network restrictions
• Contracting terms that change net-to-gross

Forecasting logic used in specialty markets

Revenue is forecast by combining:

• Treated patient counts (genotyped and eligible)
• Average net price per claim or per treated patient
• Persistence-adjusted churn and switch rates
• Share shifts driven by competition or access barriers

---

What regulatory status does CERDELGA have, and how does FDA labeling affect market penetration?

Regulatory status impacts:

• Whether new labels expand eligibility beyond strictly genotype-matched populations
• Whether post-market safety or interaction guidance changes prescribing behavior

Label constraints that affect commercial uptake

• Interaction restrictions with CYP2D6 inhibitors and inducers shape clinical eligibility.
• Label precision can reduce prescriber uncertainty, but it also limits real-world eligibility for patients on complex medication regimens.

---

What manufacturing or IP barriers could slow generic or authorized competition for CERDELGA?

Even when legal barriers fall, commercial entry can be slowed by:

• Formulation know-how and scale-up of consistent oral dosing performance
• Verified bioequivalence across metabolizer-relevant dosing regimens
• Supply chain stability and specialty distribution readiness

Commercial implication: delayed supply and restricted launch stores can soften uptake curves.

---

Key takeaways

• CERDELGA’s market is structurally constrained by CYP2D6 genotype matching, which limits addressable patient pool and slows therapy switching.
• Sales durability is driven by patent/exclusivity duration and the absence (or timing) of credible generic ANDA challenges and litigation outcomes.
• Financial trajectory is shaped more by payer contracting, prior authorization barriers, and rebate pressure than by unit pricing alone, with net-to-gross swings driving profitability even in stable volumes.
• After any legal entry trigger, branded declines are often gradual in specialty genetics markets because physicians and payers preserve therapy continuity unless access terms change materially.

---

FAQs

1. How does CYP2D6 genotype testing influence CERDELGA prescribing rates and market growth?
2. What indicators best predict when CERDELGA sales will accelerate or decelerate: formulary updates, litigation milestones, or new patient starts?
3. How quickly do payers typically switch to an ANDA after approval for a niche specialty drug like CERDELGA?
4. Which CERDELGA label restrictions most commonly block real-world use and drive discontinuation risk?
5. What competitor actions in Gaucher disease (oral vs IV) most directly pressure CERDELGA net revenue?

---

References

No sources were provided in the prompt to cite specific CERDELGA patent numbers, Orange Book listings, litigation outcomes, FDA milestones, or financial figures.

DrugChatter Q&A for CERDELGA

Cerdelga patent in portugal?
Cerdelga patent expiration date?
Cerdelga fda approval date?